Stock Performance and Market Reaction - Moderna shares surged 12% to $47 53 on Tuesday driven by investor optimism around the company's development of an H5N1 bird flu vaccine following the first reported death linked to the disease in the US [2][10] - The stock has shown a strong start to the year after losing more than half of its value in 2024 due to declining demand for its Covid-19 products [3] - The stock closed decisively above the 50-day moving average on the highest trading volume since December's triple witching session indicating bullish momentum [4][10] Technical Analysis and Key Price Levels - The relative strength index (RSI) confirms bullish momentum with a reading above 65 but remains below overbought levels suggesting room for further price appreciation [4] - Key overhead resistance levels to watch include $57 near the upper level of a consolidation period from October to November 2023 $72 near the early-September low and subsequent countertrend peak and $85 near a multi-month horizontal line connecting the February low with August price points [6][7] - Important support levels to monitor include $44 where the 50-day MA and a short-term trendline converge and $37 near the November swing low which could present buying opportunities during pullbacks [8] Strategic Considerations for Investors - Investors who purchased the stock at lower levels may consider offloading shares around the $85 level due to potential resistance from the falling 200-day MA [7] - A close above the $57 resistance level could signal further upward momentum potentially driving the stock toward the $72 and $85 levels [6][7] - A breakdown below the $44 support level could lead to a retest of the $37 level offering potential entry points for new investors [8]
Moderna Price Levels to Watch After Stock's 12% Surge on Tuesday